The Multiple Myeloma Market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medical development.
The Multiple Myeloma market research report provides current treatment practices, Multiple Myeloma emerging drugs, and Multiple Myeloma market share of the individual therapies, current and forecasted 7MM Multiple Myeloma market size. The Multiple Myeloma market report also covers current Multiple Myeloma treatment practice, SWOT analysis, and Multiple Myeloma unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key takeaways from the Multiple Myeloma Market Research Report
Recent Developmental Activities in the Multiple Myeloma Pipeline
Discover more about therapies set to grab major Multiple Myeloma market research report @ Multiple Myeloma Market Size
Multiple Myeloma Overview
Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States.
Multiple myeloma is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74. Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.
Multiple myeloma Epidemiology Segmentation in the 7MM
Download the report to understand which factors are driving Multiple myeloma market trends @ Multiple myeloma Market Share
Multiple Myeloma Treatment Market
The main Multiple myelomatreatment options include stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy. Also, the survival of patients with myeloma has improved due to the development and approval of new treatments. MM treatment strategies have also evolved with the emergence of new therapies with a novel mechanism of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets.
Multiple Myeloma Marketed Drugs
Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline
GlaxoSmithKline’s lead candidate, Belantamab Mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with an afucosylated, humanized IgG1 anti-BCMA monoclonal antibody conjugated by a protease-resistant maleimidocaproyl linker to a microtubule-disrupting agent, monomethyl auristatin F (MMAF). The drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa. It was approved by UDFDA and the European Commission in August 2020. This drug has received orphan drug designation from the EMA and the US FDA for multiple myeloma. Apart from this, the EMA and the US FDA have also granted PRIME designation and Breakthrough Therapy designation, respectively.
Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio
Abecma (ide-cel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy co-developed, and co-promoted by Bristol Myers Squibb and Bluebird bio for the treatment of adult patients with multiple myeloma who have received at least three prior therapies. In March 2021, the USFDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.
Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB
Pepaxto is a first-in-class anti-cancer peptide-drug conjugate that rapidly produces an alkylating payload into tumor cells. It is promptly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In February 2021, the USFDA approved Pepaxto in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
Sarclisa (Isatuximab): Sanofi
Sarclisa— a product of Sanofi is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells. It is manufactured and designed to initiate programmed tumor cell death (apoptosis) and immunomodulatory activity. In December 2017, Isatuximab received Orphan Designation for the treatment of patients with Relapsed or Refractory Multiple Myeloma by the US FDA and EMA.
Xpovio (Selinexor): Karyopharm
Karyopharm’ potential candidate Selinexor is an oral, first-in-class, selective inhibitor of nuclear export also known as SINE, compound. It has been approved by the US FDA in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. In April 2021, EMA validated the Company’s Type II Variation MAA, which seeks to expand the currently authorized indication for Nexpovio in the European Union to include, in combination with Velcade (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Validation of the application confirms the submission is complete to begin the EMA’s review process.
Darzalex (Daratumumab): Janssen Biotech
Darzalex (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. Darzalex is not chemotherapy. It is a human IgG1k monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. In November 2015, Darzalex first received the US FDA approval as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent. Recently, in April 2020, the US FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. Darzalex Faspro is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.
Multiple Myeloma Emerging Drugs
Venetoclax (ABT-199): AbbVie and Roche
Venetoclax (Venclexta, Venclyxto) is an oral B-cell lymphoma-2 (BCL-2) inhibitor developed by AbbVie and Genentech. It is used for the treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) and in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2. In March 2019, the US FDA placed a partial clinical hold on Venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase III trial (NCT02755597). In June 2019, the US FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol (Myeloma Positive for the t(11;14) Genetic Abnormality), including new risk mitigation measures, protocol-specified guidelines, and updated futility criteria (AbbVie News Center, 2019).
Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M): Janssen Biotech/Nanjing Legend Biotech
Ciltacabtagene Autoleucel is currently being investigated for the treatment of patients with multiple myeloma who have received at least three prior regimens, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and have documented disease progression within 12 months of starting the most recent therapy, or are double refractory to an immunomodulatory drug and a proteasome inhibitor. This product is being evaluated under licensing and collaboration agreements between Janssen and Legend Biotech. In the first quarter of 2021, the rolling submission of a Biologics License Application (BLA) to the USFDA was completed by Janssen, for cilta-cel, for the treatment of adults with relapsed or refractory multiple myeloma. Additionally, in April 2021, the company has also submitted the MAA to the EMA for cilta-cel (Legend Biotech, 2021b).
REGN5458: Regeneron Pharmaceuticals
REGN5458 is a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. In December 2019, the company presented the results at the American Society of Hematology (ASH) Annual Meeting. Currently, REGN5458 monotherapy is being investigated in an open-label, Phase I/II (NCT03761108) dose-escalation trial in patients with relapsed or refractory multiple myeloma who are at least triple refractory to existing therapeutic options, including proteasome inhibitors, immunomodulatory drugs, and CD38 antibody treatments.
Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
Iberdomide is an investigational cereblon E3 ligase modulator compound with enhanced tumoricidal and Immunostimulatory activities that induces degradation of transcription factors Aiolos and Ikaros, thereby inhibiting the growth of myeloma cells in vitro. In pre-clinical models, iberdomide has demonstrated the ability to destroy tumor cells, stimulate an immune response, overcome resistance to immunomodulatory drugs, and synergize with dexamethasone, daratumumab, and bortezomib (Celgene Corporation, 2019). In December 2018, the US FDA has granted orphan drug designation to iberdomide for the treatment of multiple myeloma.
Multiple Myeloma Key Companies and Pipeline Therapies
Download the report to understand which factors are driving Multiple Myeloma Market Trends @ Multiple Myeloma Market Outlook
Scope of the Multiple Myeloma Market Research Report
Table of Content
1. Key Insights
2. Multiple Myeloma Report Introduction
3. Multiple Myeloma Market Overview at a Glance
4. Multiple Myeloma Executive Summary
5. Multiple Myeloma Epidemiology and Market Forecast Flow
6. Disease Background and Overview
8. Multiple Myeloma Treatment
9. Multiple Myeloma Epidemiology and Patient Population
10. Patient Journey
11. Key Endpoints in Multiple Myeloma
12. Multiple Myeloma Marketed Therapies
13. Multiple Myeloma Emerging Therapies
14. Multiple Myeloma: Eight Major Market Analysis
15. Market Access and Reimbursement of Multiple Myeloma Therapies
16. Multiple Myeloma Market Drivers
17. Multiple Myeloma Market Barriers
18. Multiple Myeloma SWOT Analysis
19. Multiple Myeloma Unmet Needs
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Got Queries? Consult with our Business Expert @ Multiple Myeloma Market Drivers and Barriers
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
